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Serum levels of interleukin 6 in patients with lung cancer
H Yanagawa, S Sone, Y Takahashi, T Haku, S Yano, T Shinohara and T Ogura
Third Department ofInternal Medicine, The University of Tokushima, School ofMedicine, Kuranoto-cho 3, Tokushima 770,
Japan.
Sinary Serum interleukin 6 (IL-6) levels were measured in 75 patients with lung cancer and in 20 patients
with benign lung diseases. IL-6 was detectable in 29 patients with lung cancer (39%), but was not detectable in
any of the patients with benign lung diseases. Serum C-reactive protein levels and plasma fibrinogen levels
were significantly higher and serum albumin concentration was significantly lower in lung cancer patients with
detectable serum IL-6 levels than in those without detectable serum IL-6 levels and in patients with benign
lung diseases. On the other hand, no significant difference was observed in blood platelet counts in these three
groups. Moreover, serum IL-6 levels were not significantly different in lung cancer patients with or without
clinically demonstrated distant metastasis. These results suggest that IL-6 may be a mediator of various
reactions including an inflammatory response in lung cancer patients.
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Interleukin 6 (IL-6) is known as a multifunctional cytokine
which plays a central role in the host defence mechanism by
regulating immune responses, haematopoiesis and acute-
phase reactions (Kishimoto, 1989). Recently, much attention
has been focused on its role in the pathogenesis and progres-
sion of various malignancies. It has been reported that IL-6
is an autocrine growth factor for renal cell carcinoma cells
(Miki et al., 1989; Koo et al., 1992) and that IL-6 is pro-
duced by other non-haematopoietic tumour cells, including
bladder carcinoma (Rawle et al., 1989), ovarian carcinoma
(Watson et al., 1990) and glioblastoma (Meir et al., 1990). In
animal systems, IL-6 appears to have an important role in
mediating cancer cachexia (Strassmann et al., 1992). More-
over, elevation of the serum IL-6 level is an adverse prog-
nositic factor in patients with metastatic renal cell carcinoma
(Blay et al., 1992). However, there is still little information
about the role of IL-6 in vivo in patients with various malig-
nancies.
In patients with lung cancer, we have already reported that
malignant pleural effusions contain IL-6 (Yanagawa et al.,
1992), and we (Mizuno et al., 1994) and others (Matsuguchi
et al., 1991) have reported that several lung cancer cell lines
constitutively produce IL-6 in vitro. To clarify further the
role of IL-6, we examined serum levels of IL-6 in patients
with lung cancer. The relationship between serum IL-6 levels
and the characteristics of the patients was also analysed.
Materials and methods
Patients
Seventy-five patients with lung cancer were examined before
receiving anti-cancer therapy in Tokushima University Hos-
pital. Lung cancer was diagnosed by either histological or
cytological examination of sputum or specimens obtained by
bronchofibrescopy, percutaneous needle biopsy or thoraco-
tomy. Lung cancer was staged according to the tumour-
node-metastasis classification system (Union Internationale
Contre le Cancer, 1987). The clinical characteristics of the
patients are summarised in Table I. No significant difference
was observed in age between any groups. All patients showed
no signs of complications that might affect serum IL-6 levels,
such as infection or collagen diseases. A further 20 patients
with benign lung diseases (14 old inactive tuberculoma, four
benign granuloma, one idiopathic haemoptysis and one idio-
pathic paralysis of the phrenic nerve) were also examined as
controls.
Serun sarnpling and storage
Serum samples obtained before anti-cancer therapy were
stored at -70°C until assay for IL-6.
Enzyme immunoassay ofIL-6
Serum levels of IL-6 were assayed essentially as described
previously (Yanagawa et al., 1992). In brief, microtitre plates
(Nunc, Naperville, IL, USA) were coated with anti-IL-6
monoclonal antibody in 100 per well phosphate-buffered
saline (PBS). After overnight incubation at 4°C, the wells
were blocked with 0.1% bovine serum albumin (BSA) in PBS
and washed three times. Volumes of 200 MI of test samples
were added to the duplicate wells. The plates were incubated
at 37C for 24 h. After washing, 100 fl of mouse anti-IL-6
antibody was added to each well. The plates were then
incubated for 2 h at 37C, washed three times, supplemented
with 100 il of peroxidase-labelled rabbit anti-mouse IgG +
IgA + IgM (H + L) (Zymed Laboratories, San Francisco,
CA, USA) and incubated at room temperature for 2 h.
Finally the plates were washed five times, 1001 of enzyme
substrate (1 mgml-' O-phenylenediamine (OPD) in 0.1 M
sodium citrate buffer, pH 5.0) was added to each well and the
plates were incubated at room temperature for 5 min. The
reaction was stopped by adding 100I l of sulphuric acid to
each well, and the absorbance of 492 nm was determined
using a Titertek Multiscan. The sensitivity limit is 20 pg ml-'
and lower levels were considered undetectable.
Measurement ofbloodplatelet counts and levels ofC-reactive
protein, albwnin andfibrinogen
Blood platelet counts, plasma fibrinogen levels and serum
levels of C-reactive protein (CRP) and albumin were measur-
ed as a routine examination in our hospital.
Statistical anatysis
Results are expressed as means ± standard error of the mean.
The statistical significance of differences between groups was
analysed by Student's t-test. Data were considered statis-
tically significant if P-values were <0.05.
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Results
Serum IL-6 levels in patients with lung cancer
Of 75 patients with lung cancer, 29 (39%) had detectable
serum IL-6 levels. The individual data for cancer histological
types are shown in Figure 1. IL-6 was detected in 12 of 24
patients (50%) with squamous cell carcinoma, in 10 of 27
patients (37%) with adenocarcinoma, in 6 of 20 patients
(30%) with small-cell carcinoma and one of four patients
(25%) with large-cell carcinoma. In contrast, no patient with
benign lung diseases had detectable serum IL-6 levels.
Although Ershler et al. (1993) reported that the plasma levels
of IL-6 rise with advancing age, there was no significant
difference in age between any of the groups in the present
study, as shown in Table I.
Levels ofCRP andfibrinogen in lung cancerpatients with or
without detectable serum IL-6 levels
Since IL-6 is reported to stimulate hepatic protein synthesis
in vitro (Ramadori et al., 1988; Castell et al., 1989), we
examined hepatic protein levels in lung cancer patients and
patients with benign lung diseases. Serum CRP and plasma
fibrinogen were examined as hepatic proteins. As shown in
Figure 2, patients with detectable serum IL-6 levels had
significantly higher serum CRP levels (65.9 ± 2.9 mg 1') than
patients without detectable serum IL-6 levels (18.2 ±
0.9 mg l'; P<0.05) and patients with benign lung diseases
(8.1 ± 0.7 mg dl-1; P<0.01). Moreover, as shown in Figure
3, patients with detectable serum IL-6 levels had significantly
higher plasma fibrinogen levels (4.67 ± 0.65 g 1') than
patients without detectable serum IL-6 levels (3.80 ±
0.38 g I-'; P<0.05) and patients with benign lung diseases
(3.21 ± 0.70 g -l1; P<0.05).
Serum albumin concentration in lung cancerpatients with or
without detectable serum IL-6 levels
It has already been reported that serum albumin concentra-
tion can be considered as a marker of nutritional status in
clinically ill patients (Blackburn et al., 1977). To investigate
nutritional status in patients with detectable serum IL-6
levels, we examined serum albumin concentration in lung
cancer patients with or without detectable serum IL-6 levels
as well as in patients with benign lung diseases. As shown in
Table II, lung cancer patients with detectable serum IL-6
levels had a significantly lower serum albumin concentration
than those without detectable serum IL-6 levels and patients
with benign lung diseases (P<0.05).
Bloodplatelet counts in lung cancerpatients with or without
serum IL-6 levels
Since there are several reports demonstrating that IL-6 has
thrombopoietic functions in vitro (Ikebuchi et al., 1987;
Ishibashi et al., 1989), we studied the possible correlation
between serum IL-6 concentrations and blood platelet
counts. As shown in Figure 4, there was no significant differ-
ence in blood platelet counts between lung cancer patients
with detectable (26.5 ± 0.51 x 104il-1) or undetectable
(26.1 ± 0.20 x 104ylh 1) serum IL-6 levels or patients with
benign lung diseases (30.1 ± 0.33 x 104 ll-1).
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Figure 2 Mean serum CRP levels in patients with benign lung
diseases and in lung cancer patients with undetectable and detec-
table serum IL-6 levels. NS, not significant.
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Figure 1 Serum IL-6 levels in patients with various types of lung
cancer and with benign lung diseases. The lower limit ofdetection
for the assay was 20 pgml-'.
Table I Clinical data of patients with benign lung diseases and
patients with lung cancer
No. of Mean age
patients (years) (range) Sex
Benign lung diseases 20 60.0 (23-78) 14M/6F
Lung cancer 75 64.5 (44-85) 62M/13F
Squamous cell carcinoma 24 65.8 (45-85) 23M/IF
Adenocarcinoma 27 63.0 (44-83) 18M/9F
Small-cell carcinoma 20 66.2 (54-80) 17M/3F
Large-cell carcinoma 4 59.0 (45-68) 4M/OF
There was no significant difference in age between any groups.
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Figure 3 Mean plasma fibrinogen levels in patients with benign
lung diseases and in lung cancer patients with undetectable and
detectable serum IL-6 levels. NS, not significant.
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Fge 4 Mean blood platelet counts in patients with benign
lung diseases and in lung cancer patients with undetectable and
detectable serum IL-6 levels. No significant differences between
the groups were seen.
Table I Serum albumin concentration in patients with benign lung
diseases and in patients with lung cancer with or without detectable
serum IL-6 levels
Albwnin (gd7-')
Lung cancer patients
with detectable IL-6 levels 3.56 ± 0.02a
without detectable IL-6 levels 3.81 0 0.40O
Patients with benign lung diseases 4.01 ± 0.02b
aMean ± s.e.m. bStatistically significant (P< 0.05) compared with
the data in lung cancer patients with detectable IL-6 levels.
TabIk IL-6, CRP and fibninogen levels in patients with various
clinical stages of lung cancer
Clinical stage IL-6 (pgm1-') CRP (mgt'}Fitb (gi-')
M-factor 0
Stage I (n = 7) 10.84± 2.70b 0.9 ± 0.1 2.76 ± 0.1
StageII(n=l) 0 0.5 3.1
Stage IILA (n = 10) 68.82 ± 9.86 32.4 ± 5.7 4.38 ± 0.3
Stage IIIB (n = 17) 30.28 ± 2.72 53.8 ± 4.6 4.31 ± 0.1
Total (n = 35) 36.54 1.84 39.4 1.9 4.00 0.1
M-factor 1
Stage IV (n=40) 35.26 2.05 32.4± 1.4 4.26 ±0.1
aFibrinogen. bMean ± s.e.m.
At the same time, blood leucocyte counts were also exam-
ined in patients with these three groups. The absolute
leucocyte counts were 9092 ± 293 g1-' in lung cancer patients
with detectable IL-6 levels, 7209 ± 97 1I- ' in lung cancer
patients without detectable IL-6 levels and 6095 ± 86jil' in
patients with benign lung diseases. Lung cancer patients with
detectable serum IL-6 levels had significantly higher blood
leucocyte counts than patients with benign lung diseases
(P<0.05).
Serwn IL-6 and CRP levels andplasmafibrinogen levels in
patients with various clinical stages of lung cancer
We examined serum IL-6 and CRP levels and plasma fibnrn-
ogen levels in lung cancer patients with disease of different
clinical stages. The data are shown in Table III. Although
IL-6 and CRP levels were non-significantly lower in patients
with stage I disease than in patients with stage IIIA, IIIB and
IV disease, and plasma fibrinogen levels were significantly
lower in patients with stage I disease than in those with stage
IIIB and IV disease, there was no significant difference in
serum IL-6 and CRP levels and plasma fibrinogen levels
between patients with or without clinically demonstrated dis-
tant metastasis.
In the present study. we demonstrate that patients with lung
cancer have elevated levels of IL-6, and that lung cancer
patients with detectable serum IL-6 levels have significantly
higher CRP and fibnrnogen levels and lower albumin concen-
tration than those without serum IL-6 levels and patients
with benign lung diseases.
Elevated serum IL-6 levels have already been reported in
elderly subjects (Ershler et al., 1993) and in patients with
various non-malignant diseases, including pneumonia
(Moussa et al., 1994), thermal injury (Nijsten et al., 1987),
sepsis (Helfgott et al., 1989), human iunmunodeficiency virus
(HIV)-related diseases (Breen et al., 1990), rheumatoid
arthritis (Houssiau et al., 1988) and systemic lupus erythema-
tosus (Spronk et al., 1992). In the present study, there was no
significant difference in age between patients with benign
lung diseases and patients with lung cancer of various histo-
logical types, and patients with possible complications of
benign diseases in which elevated serum IL-6 levels have been
reported were strictly excluded. The mechanism responsible
for the elevated levels of serum IL-6 in lung cancer patients
remains unclear. It could be the result of abnormal produc-
tion by tumour cells or a response of the immune system im
the tumour-bearing state.
IL-6 is known to induce production of acute-phase pro-
teins by hepatocytes (Ramadori et al., 1988; Castell et al..
1989). In our study, as observed previously by others in
patients with renal cell carcinoma (Blay et al., 1992), serum
CRP levels in patients with detectable serum IL-6 levels were
significantly higher than in those with undetectable levels.
Moreover, as shown in Figure 3, plasma fibrinogen levels had
the same correlation as CRP with serum IL-6 levels.
We have found that lung cancer patients with detectable
serum IL-6 levels have lower serum albumin concentrations
than those without detectable serum IL-6 levels. Dosquet et
al. (1994) have already reported that renal cell carcinoma
patients who experience weight loss have higher blood IL-6
levels than those without weight loss. As reported in animal
models (Strassmann et al., 1992), systemic IL-6 can be con-
sidered a mediator of malnutrition in lung cancer patients.
Megakaryocytopoiesis, resulting in the production and
release of platelets, is regulated by various cytokines, includ-
ing IL-1, IL-2, IL-3, IL-6, IL-7, IL-l1, granulocyte colony-
stimulating factor (CSF), macrophage CSF and
granulocyte-macrophage CSF (Ogawa, 1993). Among these,
IL-6 is reported to stimulate platelet production in animal
models (Asano et al., 1990; Hill et al., 1990). Moreover,
increased blood platelet counts were observed in a phase I
study of subcutaneous administration of IL-6 (Wever et al.,
1993). Nevertheless, no significant thrombocytosis was
observed in patients with detectable serum IL-6 levels in the
present study. The reason for this discrepancy is unclear, but
it is possible that the elevated IL-6 levels observed in patients
with lung cancer are lower than required for stimulation of
thrombopoiesis or that other additional cytokines necessary
for thrombopoiesis were lacking in these patients.
There are several reports suggesting that IL-6 contributes
to tumour progression directly and indirectly through inhibi-
tion of the anti-tumour response by host cells. In a murine
model, IL-6 has been shown to enhance tumour progression,
and local inhibition by IL-6 of the anti-tumour response by
tumour-infiltrating lymphocytes has been suggested (Tanner
and Tosato, 1991). Moreover, Dosquet et al. (1994) have
reported that renal cell cancer patients with disseminated
disease have higher blood IL-6 levels than those with
undisseminated disease. On the other hand, detectable serum
levels of IL-6 are less and less frequent with progression of
IB-cll chronic lymphocyic leukemia (Aderka et at., 1993). In
the present study, no statistical difference in serum IL-6 levels
was observed in lung cancer patients with or without
clinically demonstrated distant metastasis. Although the
reason for this discrepancy is unclear, one possible explana-
tion is the heterogeneity of the effect of IL-6 on growth of
various tumour cells. An autocrine role for IL-6 in renal cellSew L4 lew in Wl cm= x4 H Yanwa et a
ir1
carcinoma (Miki et al., 1989; Koo et al., 1992) as well as
multiple myeloma (Kawano et al., 1988) and lymphoma (Yee
et al., 1989) has been reported, but Tak-izawa et al. (1993)
reported that IL-6 may function as a growth-inhibiting factor
in the proliferation of human lung cancer cell lines.
Heterogeneity in the roles of IL-6 in vivo must be considered
in various malignancies, and even in patients with lung
cancer. Moreover, the presence of other soluble factors, such
as soluble IL-6 receptor (Honda et al., 1992), may affect the
activity of IL-6 in vivo.
In summary, it is demonstrated in the present study that
IL-6 may contribute to various reactions in patients with
lung cancer. Further investigation is warranted to clarify the
exact role of IL-6 in various malignancies.
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